Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02223819
Title Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center, Pfizer
Indications

necrotic uveal melanoma

mixed cell uveal melanoma

posterior uveal melanoma

uveal melanoma

Therapies

Crizotinib

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Mount Sinai Comprehensive Cancer Center Miami Beach Florida 33140 United States Details
Columbia Univeristy Medical Center New York New York 10032 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
The Ohio State University Columbus Ohio 43210 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field